Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study

@inproceedings{Cohen2018DesignAR,
  title={Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study},
  author={Alexander A. Cohen and Cihan Ay and Philippe Hainaut and Herv{\'e} D{\'e}cousus and Ulrich Hoffmann and Sean Patrick Gaine and Michiel Coppens and Pedro Marqu{\'e}s da Silva and David Jim{\'e}nez and Beatrice Amann-Vesti and Bernd Br{\"u}ggenj{\"u}rgen and Pierre L{\'e}vy and Julio L{\'o}pez Bastida and {\'E}ric Vicaut and Petra Laeis and Eva-Maria Fronk and Wolfgang Zierhut and Thomas Malzer and Peter Bramlage and Giancarlo Agnelli},
  booktitle={Thrombosis Journal},
  year={2018}
}
  • Alexander A. Cohen, Cihan Ay, +17 authors Giancarlo Agnelli
  • Published in Thrombosis Journal 2018
  • Medicine
  • BackgroundVenous thromboembolism (VTE, including deep vein thrombosis [DVT] and pulmonary embolism [PE]) has an annual incidence rate of 104–183 per 100,000 person-years. After a VTE episode, the two-year recurrence rate is about 17%. Consequently, effective and safe anticoagulation is paramount. Edoxaban is a direct oral anticoagulant (DOAC) approved VTE treatment. Current safety and efficacy data are derived from clinical trials, and information about treatment durations beyond 12 months are… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    20
    Twitter Mentions

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 19 REFERENCES

    Guidelines for good pharmacoepidemiology practice (GPP).

    • Medicine
    • Pharmacoepidemiology and drug safety
    • 2016

    Epidemiology of venous thromboembolism

    VIEW 1 EXCERPT